Relapsed or Refractory Multiple Myeloma Video Perspectives

In this video playlist, Rahul Banerjee, MD, assistant professor in the clinical research division at Fred Hutchinson Cancer Center, discussed:

• the latest developments in the treatment and study of relapsed/refractory multiple myeloma, including insight into the study of measurable residual disease;
• the impact that chimeric antigen receptor T-cell therapy has made on multiple myeloma, which he said has allowed doctors to “change their paradigm”;
• how CAR-T has helped change outcomes in multiple myeloma, and relevant data from the KarMMa-3 trial;
• insight into specific indicators of relapse in multiple myeloma, a major subject of debate over the last 20 years;
• how he approaches predicting and treating multiple myeloma relapse in his own practice; and
• the biggest unmet needs in the treatment of relapsed/refractory multiple myeloma, and obstacles towards curing the disease.